“Bimekizumab Response Maintenance through Two Years of Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Responded After 16 Weeks: Interim Results from the BE BRIGHT Open-Label Extension Trial”. SKIN The Journal of Cutaneous Medicine 5, no. 6 (November 5, 2021): s52. Accessed April 30, 2026. https://skin.dermsquared.com/skin/article/view/1403.